Trial · NCT02647762
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
NCT02647762, Phase 3, Terminated, Can-Fite BioPharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis. Trials, record NCT02647762. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02647762
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
- NCT number
- NCT02647762
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 244 participants, actual
- Lead sponsor
- Can-Fite BioPharma
- Conditions
- Rheumatoid Arthritis
- Interventions
- CF101 1 mg, CF101 2 mg, Placebo, MTX
- First posted
- 2016-01-06
- Last updated
- 2020-12-19
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of oral CF101, BID for 12 weeks to subjects with active rheumatoid arthritis (RA) relative to oral methotrexate (MTX) as assessed by the proportion of subjects achieving a Disease Activity Score (DAS) of Low Disease Activity (LDA) | 12 weeks | Proportion of subjects achieving Disease Activity Score (DAS) (based on Erythrocyte Sedimentation Rate) of Low Disease Activity (\<3.2, where lower scores indicate lower disease activity) at Week 12 |
| Primary | Assess the adverse event profile of daily oral CF101 under the conditions of the trial | 24 weeks | Nature, incidence and severity of treatment-emergent adverse events (TEAEs) |
| Primary | Describe the pharmacokinetics (PK) of CF101 under the conditions of the trial | 24 weeks | Plasma CF101 levels will be determined |
| Secondary | Determine the efficacy of oral CF101 when administered daily for 24 weeks to subjects with active RA relative to oral MTX, as assessed by the proportion of subjects achieving DAS remission | 24 weeks | Change and percent change from baseline in DAS28 |
| Secondary | Explore the relationship between whole blood adenosine A3 receptor (A3AR) expression and treatment response | 24 weeks | A3AR expression will be assessed on whole blood samples |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02647762
GET https://conductscience.org/api/trials/v1/NCT02647762/registered